Prosom
(estazolam 1)Phase 3Small molecule
Prosom is one of 42 small molecule programs targeting Insomnia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Insomnia
#DrugCompanyPhaseTrials
1Rozerem
TakedaApproved
Dayvigo
EisaiApproved
Ambien
PPurdue Pharma LP
Approved
Lunesta
Akero TherapeuticsApproved
Lexapro
AbbVieApproved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Raldesy
PPragma
Approved
Quviviq
Idorsia Pharmaceuticals Ltd.Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Bayer Aspirin
BayerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 26, 1990
PROSOM
NDA NDA019080
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for estazolam 1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]